Walters Group bought 4,335,000 shares of Zentalis Pharmaceuticals, Inc. at $3.50 for $15.2M on Aug 14, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$15,172,500Shares × reported price
Shares traded
4,335,000Common Stock
Price per share
$3.50Reported price. Read footnotes for ranges.
% of reported position traded
32.09%This security and ownership context
Holdings after
17,844,973Direct
Trade date
Aug 14, 2026Buy
Filed
Aug 19, 2026, 6:11 PM ET5-day reporting delay
Accession
0001213900-26-091823Code P · Transaction 11922
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 13,509,973 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ZNTL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ZNTL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +25%1w ago +10%1d ago +8.6%
Returns since7d +1.8%30d −19%90d180d1y

Footnotes in full

F1: The shares of common stock reported herein (the "Shares") are held directly by The Walters Group (the "TWG"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose.